Antimicrobial resistance has been a problem for the treatment of gonorrhoea since the introduction of sulfa drugs in the 1930s. The gonococcus has a remarkable ability to obtain the genetic elements required to develop resistance and for these resistant strains to then widely disseminate. Medicine' was that drugs were of little value 3 . Intravenous mercurochrome, a complex of fluorescein, bromine and mercury, was later introduced, which was then combined with urethral irrigations of potassium permanganate.
The chemotherapy era of gonorrhoea treatment
The chemotherapy era of gonorrhoea treatment was heralded by the 1937 introduction of the much more effective sulfanilamide at the Johns Hopkins University Clinic and then in London where a three-week course achieved an 80% cure rate. Sulfanilamide was then superseded by the analogue sulfathiazole, which was better tolerated with a shorter treatment course. However, by the 1940s resistance to sulfonamides was found and heat treatment was reintroduced with the sulfonamide for better cure rates.
A significant advance in treatment occurred with the introduction of penicillin, which was almost universally curative, even with low doses of relatively impure product. Such was the euphoria at the time that penicillin was advertised as curative in four hours and was provided free by health departments. However, in a repeat of the sulfonamide experience cases resistance to penicillin became more frequent through the 1950s. The response was to increase the penicillin dose from 1.5 g to 2.4 g, replace penicillin with amoxicillin which had a better oral bioavailability and pharmacodynamics, and finally in 1969 to combine amoxicillin with probenecid to return the cure rates to 95% or better.
The demise of penicillins as a reliable treatment for gonorrhoea was due to the 1976 appearance of plasmid-mediated penicillinase production resulting in high level resistance 
Combination therapy for gonorrhoea
To respond to the looming threat of widespread ESC resistance a review of current guidelines was warranted, with the options being to increase the dose of the cephalosporin, combine it with another antibiotic with a different mechanism of action, or move to another antibiotic class. 
The multidrug-resistant and extensively drugresistant era of gonorrhoea treatment
A new scheme to define multidrug-resistant N. gonorrhoeae (MDR NG) and extensively drug-resistant N. gonorrhoeae (XDR NG) was proposed by Tapsall et al. 17 in 2009 to focus attention on gonococcal strains with resistance to antibiotics in current use rather than on those antibiotics superseded or not used for treatment of gonorrhoea. These definitions (Table 1) were soon put into practice. Until 2017, cases of MDR NG resistant to penicillin, ceftriaxone 20, 21 . These strains were resistant to ceftriaxone (MIC 0.25-0.5 mg/mL) and possessed high level azithromycin resistance (MIC >256 mg/mL). Perhaps as expected, the English case failed to clear the pharynx with 1 g ceftriaxone plus 2g spectinomycin, but was subsequently cured with intravenous ertapenem for three days. Table 2) .
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